A research group headed by James Morre, Ph.D., professor of medicinal chemistry at Purdue University, obtained results supporting that phenoxodiol (an investigational drug) may be effective in the treatment of prostate cancer by specifically targeting a protein on prostate cancer cells known as tNOX 75 alpha.
The Purdue team has identified the protein, tumor-associated NADH oxidase (or tNOX), as a pan-cancer marker. The protein is critical to the ability of the tumor cell to grow and to survive.
They also have shown that there are different forms of this protein, known as isoforms, and that different tNOX isoforms are associated with different …read more